🏹Zacks Investment Research today
Pfizer’s Second Biosimilar of Remicade Receives FDA Approval – December 14, 2017.
Zacks Investment Research / by Zacks Equity Research / 9 hours ago
Pfizer Inc. PFE announced that the FDA has approved Ixifi its second biosimilar version of Johnson & Johnson’s JNJ blockbuster rheumatoid arthritis (“RA”) drug, Remicade (infliximab). Notably, Ixifi is a chimeric human-murine monoclonal antibody against tumor necrosis factor.Zacks.com
https://www.zacks.com/stock/news/285997/pfizers-second-biosimilar-of-remicade-receives-fda-approval
RenaissanceRe Suffers from Catastrophe Loss, High Leverage – December 14, 2017.
Unprecedented catastrophe loss weighed on RenaissanceRe Holdings Ltd. (RNR – Free Report) this year, thanks to Mother Nature’s fury that took a toll on the company’s underwriting performance.
As a result, the insurer incurred net claims and claims expenses of $1.6 billion in the first nine months of 2017, significantly higher than $0.4 billion in the year-ago period
Zacks.com
General Dynamics Wins $198M Deal to Manufacture DMR Systems – December 14, 2017.
General Dynamics Corp’s GD Mission Systems business recently won a contract for the procurement, manufacturing, testing and delivery of the AN/USC-61(C) Digital Modular Radio (DMR) systems.
The defense major will also supply high frequency distribution amplifier group components, spare parts and engineering services to support field and maintenance work.
Zacks.com